Compare AbbVie Inc (ABBV) vs Applied Digital Corporation (APLD) Price & Performance

AbbVie (ABBV) trades at $254.44, showing slight daily weakness but maintaining a bullish technical structure with strong institutional support. The company has consistently beaten earnings expectations in recent quarters, with Q1 2026 EPS of $2.65 exceeding the $2.59 estimate. Revenue growth is accelerating, reaching $61.16B in 2025, while the immunology portfolio (Skyrizi, Rinvoq) successfully offsets Humira declines. Analyst consensus remains strongly positive with 68% buy ratings and a $266.33 price target.

The outlook is constructive with robust pipeline developments and dividend growth, though elevated valuation multiples (P/E 124.83, P/B 245.29) and looming patent cliffs in the 2030s present risks. Net income margin compression from 20.38% in 2022 to 6.9% in 2025 requires monitoring, but strong cash generation ($19.03B operating cash flow) supports continued shareholder returns.

Applied Digital (APLD) trades at $33.50, up 1.33% with a bearish technical signal despite bullish oscillators. The company shows rapid revenue growth but significant losses, with a -58.38% net margin and negative cash flow from operations. Recent developments include major AI data center expansions and $36 billion in contracted backlog, though profitability remains elusive amid heavy capital spending.

Outlook remains speculative with strong analyst support (100% buy ratings, $71.43 target) but substantial execution risks. The stock offers high-growth AI infrastructure exposure but faces customer concentration, mounting debt, and uncertain path to profitability. Current valuation at 27x sales appears rich given negative earnings and cash flow challenges.